Skip to NavigationSkip to content

China approves first homegrown HPV vaccine

Published on 08/01/20 at 01:07pm

Female patients in China between the ages of nine and 45 will have access to the country’s first domestically-produced vaccine for the prevention of cancerogenic human papillomavirus (HPV) after the approval of Innovax’s Cecolin therapy by the National Medical Products Administration (NMPA).

Cecolin protects against Type 16 and 18 HPV, the two most common strains of the virus that can lead to cervical cancer. The approval presents an alternative therapy in a space occupied by only two other countries worldwide: GlaxoSmithKline, headquartered in the UK which produces a two-valent vaccine, and MSD in the US, which produces a four- and nine-valent vaccine.

According to the NMPA, the move was made in response to rising public demand for a HPV vaccine in order to generate greater access. The country said it would aim to accelerate the review and approval of domestically produced HPV vaccines.

The development is emblematic of a concerted effort from China to reduce its reliance on importing medicine from outside its borders and follows within a week the news that the NMPA had approved its first homegrown 13-valent pneumonia vaccine.

Matt Fellows

Comments

WOw! A really nice article. In this article, the author describes the duties of NMPA. CBD For Cancer Patients The first time I heard about NMPA but now, I understood its functions. I am so happy to read this article.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches